American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase After ≥2 Prior Tyrosine Kinase Inhibitors: Update After 48 Weeks

Mauro M

  • Presentation # 310 – Oral
    December 11, 2021 | 04:45 PM EST

This presentation will be available once the congress embargo lifts

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase Without or With T315I Mutations

Andorsky D

  • Presentation # 3599 – Poster
    December 13, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts

Real-world Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy

Breccia M

  • Presentation # 1943 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts

Trial in Progress: A Multicenter, Open Label, Randomized Phase III Study of Asciminib (80 mg Once Daily) vs Investigator-selected TKIs in Newly Diagnosed Adult Patients With Chronic Myeloid Leukemia in Chronic Phase

Cortes JE

  • Presentation # 1478 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts

Treatment Patterns in Patients With Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-world Evidence

Dahlen T

  • Presentation # 1485 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts

Trial in Progress: A Multicenter, Open-label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Philadelphia Chromosome–positive Chronic Myeloid Leukemia in Chronic Phase Treated With ≥1 Prior Tyrosine Kinase Inhibitor

Hijiya N

  • Presentation # 2561 – Poster
    December 12, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts

Clinical Characteristics and Late-line Treatment Patterns of Patients With Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Patel P

  • Presentation # 5036 – Publication Only

This presentation will be available once the congress embargo lifts

Patient and Physician Perspectives of Unmet Needs in CML – Designing the CML SUN Survey

Pemberton-Whiteley Z

  • Presentation # 4986 – Publication Only

This presentation will be available once the congress embargo lifts

Treatment-Free Remission (TFR) After Two Different Durations of Nilotinib Consolidation in Patients With Chronic Myeloid Leukemia (CML) Previously Treated With Imatinib: ENESTPath Study Results

Rea D

  • Presentation # 635 – Oral
    December 13, 2021 | 11:30 AM EST

This presentation will be available once the congress embargo lifts

First Interim Analysis of the Italian DANTE Study: De-escalation Before Treatment-Free Remission in Patients With Chronic Myeloid Leukemia Treated With First-line Nilotinib

Breccia M

  • Presentation # 1474 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound